Swiftmerge Acquisition Corp. — Q3 2023 Form 10-Q
Entity note: The filing is for Swiftmerge Acquisition Corp., not Aleanna, Inc. It covers the quarter and nine months ended September 30, 2023; financial statements are unaudited.
Business context
Swiftmerge is a special purpose acquisition company (SPAC) with no operating business or revenue. It was searching for a business combination and, on August 11, 2023, agreed to merge with HDL Therapeutics, Inc. The transaction remains subject to conditions, including shareholder approval, and is not assured to close.
Financial results and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Operating revenue | $0 | $0 | $0 | $0 |
| Formation and operating costs | $850,085 | $218,553 | $3,281,394 | $1,000,286 |
| Unrealized gain on Trust Account investments | $1,198,052 | $610,923 | $6,212,416 | $933,679 |
| Net income (loss) | $347,967 | $392,370 | $2,931,022 | $(96,607) |
| Net income (loss) per share, basic and diluted | $0.04 | $0.01 | $0.17 | $0.00 |
Profit reflected investment gains in the Trust Account, not operating earnings; operating margins are not meaningful for this pre-combination SPAC. For the first nine months, operating cash use was $792,137. Cash outside the Trust Account was $69,777 at quarter-end, versus $461,914 at December 31, 2022. Trust investments were $24,086,806, down from $229,792,494, principally after shareholder redemptions of $211,918,104 in June 2023.
Current liabilities were $3,416,169, including a $400,000 non-interest-bearing Sponsor promissory note; working capital deficit was $3,218,146. The note is due at a business combination or liquidation and may be converted into warrants at the Sponsor’s option. Shareholders’ deficit was $3,118,146. The filing reports no long-term debt or off-balance-sheet arrangements.
Material changes and transaction terms
- At the June 2023 shareholder meeting, the deadline to complete a business combination was extended to March 15, 2024. Holders redeemed 20,253,090 public shares for approximately $211.9 million. The Sponsor converted 3,375,000 founder shares into non-redeemable Class A shares.
- The proposed HDL merger values consideration for HDL shareholders at $400 million in cash and shares, with Swiftmerge to be renamed HDL Therapeutics, Inc. Eligible HDL holders may receive up to 11 million additional shares if specified post-closing share-price milestones are met.
- HDL is to use commercially reasonable efforts to raise up to $2.68 million through December 31, 2023 and an additional $3 million thereafter. Certain pre-closing obligations depend on raising these funds or HDL’s ability to pay its expenses.
Outlook, risks, and unusual items
- Management states that available operating cash is insufficient to meet obligations through March 15, 2024 and that substantial doubt exists about the company’s ability to continue as a going concern. Additional financing is not committed; failure to close a transaction or obtain an extension would trigger liquidation.
- Disclosure controls were deemed ineffective due to a material weakness involving an unbilled third-party service-provider amount, failure to timely remove a waived deferred-underwriting-fee liability, and interest income accounting. The company said previously issued 2022 annual and Q1 2023 financial statements should no longer be relied upon and would be restated; it said the changes do not affect cash.
- The filing identifies uncertainty from geopolitical conflicts and a potential U.S. excise tax on certain stock repurchases. It reports no legal proceedings and no material change to other previously disclosed risk factors.
Investor facts to verify
- Confirm the filing entity: this document names Swiftmerge Acquisition Corp., despite the request metadata naming Aleanna, Inc.
- Check the status and closing conditions of the HDL merger, including shareholder approval, financing, redemption levels, and the March 15, 2024 deadline.
- Review the 2022 and Q1 2023 restated financial statements and the company’s remediation of its material weakness.
- Assess near-term liquidity and Sponsor support: quarter-end cash was $69,777, and no additional financing commitment was confirmed.
- Distinguish Trust Account investment gains from recurring operating performance; the company had no operating revenue.